{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:59:02Z","timestamp":1788537542758,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pompe disease, a rare autosomal recessive disorder caused by acid alpha-glucosidase deficiency, results in progressive glycogen accumulation and multisystem dysfunction. Enzyme replacement therapy with recombinant human acid alpha-glucosidase is the standard of care; however, some patients develop anti-recombinant human acid alpha-glucosidase antibodies, leading to reduced efficacy. This case report presents two infants with early-onset Pompe disease who developed IgG antibodies to enzyme replacement therapy and were subsequently treated with methotrexate, highlighting the importance of monitoring antibody development and exploring alternative therapeutic approaches.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Patient 1, a 10-month-old female from Bogota, Colombia, presented with generalized hypotonia, macroglossia, hyporeflexia, and mild left ventricular hypertrophy. Diagnostic tests confirmed early-onset Pompe disease, and enzyme replacement therapy was started at 12\u00a0months. Due to a lack of improvement and high anti-recombinant human acid alpha-glucosidase IgG antibody titers (1:1800), methotrexate was started at 18\u00a0months. After 8\u00a0months of combined therapy, antibody titers were negative and significant improvement in motor function was observed using the Gross Motor Function Measure 88. Patient 2, a 7-year-old female from Bogota, Colombia, was diagnosed with early-onset Pompe disease at 12\u00a0months and initiated enzyme replacement therapy. At 5\u00a0years of age, she experienced frequent falls and grip strength alterations. Functional tests revealed motor development delay, generalized hypotonia, and positive anti-recombinant human acid alpha-glucosidase IgG antibody titers (6400). Methotrexate was initiated, leading to a reduction in falls and antibody titers (3200) after 6\u00a0months, with no adverse events or complications. Motor function improvement was assessed using the Motor Function Measurement 32.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The presented cases highlight the importance of monitoring patients for anti-recombinant human acid alpha-glucosidase antibody development during enzyme replacement therapy and the potential benefit of methotrexate as an immunomodulatory agent in early-onset Pompe disease. Early diagnosis and timely initiation of enzyme replacement therapy, combined with prophylactic immune tolerance induction, may improve clinical outcomes and reduce the development of anti-recombinant human acid alpha-glucosidase antibodies. The cases also highlight the importance of objective motor function assessment tools, such as Gross Motor Function Measure 88 and Motor Function Measurement 32, in assessing treatment response. Further research is needed to optimize treatment regimens, monitor long-term effects, and address the current limitations of enzyme replacement therapy in Pompe disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-024-04638-5","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:02:21Z","timestamp":1721260941000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-2965","authenticated-orcid":false,"given":"Sandra Milena","family":"Castellar-Leones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Ortiz-Corredor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Manrique-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"S\u00e1nchez-Pe\u00f1arete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edicson","family":"Ruiz-Ospina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Soto-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Correa-Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"issue":"6","key":"4638_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","volume":"7","author":"MG Ausems","year":"1999","unstructured":"Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, Sandkuijl LA, Reuser AJ, van der Ploeg AT. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7(6):713\u20136.","journal-title":"Eur J Hum Genet"},{"issue":"s1","key":"4638_CR2","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.3233\/JND-159034","volume":"2","author":"H Balcin","year":"2015","unstructured":"Balcin H, Lindberg C, Lindvall B, Sundstr\u00f6m A, Andersson B, Hult M, Engvall MSG. Epidemiology and screening for Pompe disease in Sweden. J Neuromuscul Dis. 2015;2(s1):S38.","journal-title":"J Neuromuscul Dis"},{"issue":"15","key":"4638_CR3","doi-asserted-by":"publisher","first-page":"15856","DOI":"10.18632\/aging.103794","volume":"12","author":"S Taverna","year":"2020","unstructured":"Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, Zora M, Scalia S, Brando C, Curto AL, Marsana EM, Olivieri R, Vitale SDG. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging. 2020;12(15):15856\u201374.","journal-title":"Aging"},{"issue":"11","key":"4638_CR4","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/gim.2015.6","volume":"17","author":"KL Berrier","year":"2015","unstructured":"Berrier KL, Kazi ZB, Prater SN, Bali DS, Goldstein J, Stefanescu MC, Rehder CW, Botha EG, Ellaway C, Bhattacharya K, Tylki-Szymanska A, Karabul N, Rosenberg ASKP. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med. 2015;17(11):912\u20138.","journal-title":"Genet Med"},{"issue":"4","key":"4638_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41436-018-0270-7","volume":"21","author":"ZB Kazi","year":"2019","unstructured":"Kazi ZB, Desai AK, Troxler RB, Kronn D, Packman S, Sabbadini M, Rizzo WB, Scherer K, Abdul-Rahman O, Tanpaiboon P, Nampoothiri S, Gupta N, Feigenbaum A, Niyazov DM, Sherry L, Segel R, McVie-Wylie A, Sung C, Joseph AM, Richards SKP. An immune tolerance approach using transient low-dose methotrexate in the ERT-na\u00efve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. Genet Med. 2019;21(4):887\u201395.","journal-title":"Genet Med"},{"key":"4638_CR6","first-page":"20100475","volume":"10","author":"AK Desai","year":"2019","unstructured":"Desai AK, Kazi ZB, Bali DSKP. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. Mol Genet Metab Rep. 2019;10:20100475.","journal-title":"Mol Genet Metab Rep"},{"issue":"13","key":"4638_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21037\/atm.2019.05.27","volume":"7","author":"AK Desai","year":"2019","unstructured":"Desai AK, Li C, Rosenberg ASKP. Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review. Ann Transl Med. 2019;7(13):285.","journal-title":"Ann Transl Med"},{"issue":"5","key":"4638_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","volume":"23","author":"C Li","year":"2021","unstructured":"Li C, Desai AK, Gupta P, Dempsey K, Bhambhani V, Hopkin RJ, Ficicioglu C, Tanpaiboon P, Craigen WJ, Rosenberg ASKP. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet Med. 2021;23(5):845\u201355.","journal-title":"Genet Med"},{"key":"4638_CR9","first-page":"32100893","volume":"6","author":"S Curelaru","year":"2022","unstructured":"Curelaru S, Desai AK, Fink D, Zehavi Y, Kishnani PSSR. A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation. Mol Genet Metab Rep. 2022;6:32100893.","journal-title":"Mol Genet Metab Rep"},{"key":"4638_CR10","volume":"6","author":"AK Desai","year":"2020","unstructured":"Desai AK, Baloh CH, Sleasman JW, Rosenberg ASKP. Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: demonstration of long-term safety and efficacy in an expanded cohort. Front Immunol. 2020;6: 111727.","journal-title":"Front Immunol"},{"issue":"6","key":"4638_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/jimd.12268","volume":"43","author":"E Poelman","year":"2020","unstructured":"Poelman E, van den Dorpel JJA, Hoogeveen-Westerveld M, van den Hout JMP, van der Giessen LJ, van der Beek NAME, et\u00a0al. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients. J Inherit Metab Dis. 2020;43(6):1243\u201353.","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"4638_CR12","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.4049\/jimmunol.1303326","volume":"193","author":"MS Joly","year":"2014","unstructured":"Joly MS, Martin RP, Mitra-Kaushik S, Phillips L, D\u2019Angona A, Richards SMJA. Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa. J Immunol. 2014;193(8):3947\u201358.","journal-title":"J Immunol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04638-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04638-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:02:25Z","timestamp":1721260945000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04638-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4638"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04638-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]},"assertion":[{"value":"6 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"328"}}